About MS  > MS news and research  > Drugs  > ATL1102
About MS

What is MS?

MS symptoms

Managing your MS

Effects of MS

MS news and research

Alternative medicine

Bacteria and viruses

Biomarkers and microRNA


Brain inflammation, lesions & 'black holes'

Brain iron deposits

Cancer and MS





Ampyra (Fampyra)




Cannabis and cannabinoids

Copaxone and glatiramer acetate


Emerging therapies


Low dose naltrexone

Lemtrada (alemtuzumab)


MN-166 (ibudilast)

Nerventra® (laquinimod)

Plegridy (peginterferon beta-1a)


Rituximab (rituxan)





Trimesta (oral estriol)


Zenapax (daclizumab)

Endo-parasites and helpful organisms

Environmental factors

Ethnic groups, geographical regions and MS


Gender and MS



Immune cells


Medical imaging

MS Symptoms research

Multiple Sclerosis (etiology)


Nerves, brain cells and spinal cord

Paediatric MS


Potential viral causes

Quality of life


Sex and MS

Stem cells



Types of MS


Vitamin D

World MS Day

News and research archive

Other support

Donate with JustGiving

Latest Tweets


Oral MS Medications








Phase IIa clinical trial data of ATL1102 in MS patients published(22/09/14)

Antisense Therapeutics reports the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

The article titled “CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS”, is currently available online and will be included in the print edition Volume 83, November 11, 2014.

The article highlights the successful outcomes of the Phase IIa clinical trial of ATL1102 in Multiple Sclerosis (MS) patients where in the randomised, double-blind, placebo-controlled study in 77 patients with relapsing-remitting multiple sclerosis (RRMS), ATL1102 met its primary end point after only two months of dosing, showing a significant reduction, by 54.4% (p=0.01) in the cumulative number of new active brain lesions in patients taking ATL1102 compared to placebo.

The efficacy outcomes from this study were viewed to be as good as, or superior to, those achieved with MS drug Tysabri® at a similar stage in its clinical development. Tysabri® (natalizumab) is a monoclonal antibody drug targeting the VLA-4 receptor (same target as ATL1102). In 2013, Tysabri® generated sales in excess of US$1.6 billion. It is regarded as the current efficacy benchmark for the treatment of RRMS. ANP anticipates that ATL1102 could be as potent as Tysabri® but potentially safer, cheaper to manufacture, and more conveniently dosed.

Principal Investigator of the ATL1102 Phase IIa study and lead author of the Neurology publication, Volker Limmroth (MD PhD Professor of Neurology, Chairman Department of Neurology and Palliative Care Medicine Cologne City Hospitals, University of Cologne) said:

There are a number of unresolved issues with current MS drugs including the occurrence of neutralising antibodies to the antibody, protein and peptide MS drugs as well as long-term safety concerns with the more recently approved drugs. There is a clear need for more effective and safe drugs for the significant population of MS patients who have relapses and non-stable disease.

The ATL1102 Phase IIa trial provides evidence for the first time that antisense oligonucleotides may be used as a therapeutic approach in neuroimmunologic disorders such as MS. ATL1102 was shown to be highly effective in reducing brain lesions in RRMS patients with a quick onset of action and a clinical safety profile that strongly supports its ongoing development as a treatment for this disease.

The full article can be downloaded from http://www.neurology.org/content/early/recent 

Antisense Therapeutics CEO and Managing Director Mark Diamond said:

The Journal of the American Academy of Neurology is the most widely read and highly cited peer-reviewed Neurology Journal. Having our ATL1102 Phase II data published in such a high quality scientific journal is extremely beneficial for the future development and partnering plans for the drug and our current FDA interactions. It also provides further independent validation to the quality of our data and considerable development progress made by the Company in advancing ATL1102.

Source: News-Medical.Net Copyright 2000-2014 AZoM.com Limited (22/09/14)

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis(02/04/14)

Antisense Therapeutics Limited (“ANP” or the “Company”) is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose). The Company believes that the preclinical and clinical experience to date with ATL1102 should allow dosing in future trials at or above the 1.5 mg/kg/dose level.

Based on histologic findings in common with a previous monkey study at doses exceeding 1.5mg/kg/dose, the Company continues to evaluate the chronic monkey data with regard to potential human relevance, and safety biomarkers that may be useful in future clinical studies. Exposures achieved in this study are regarded as potentially clinically relevant based on the efficacy outcomes from the previously conducted Phase IIa trial of ATL1102 in MS patients.

Pending receipt and final data evaluation from the current study, as well as review of all the preclinical and clinical data obtained, ANP is planning future regulatory agency discussions regarding further development of ATL1102 and the dosing regimen for a future Phase IIb trial in MS patients. The Company anticipates final review of the data by June this-year and follow-up discussions with the US Food and Drug Administration (FDA) at a pre-IND meeting during the 3rd quarter 2014.

Antisense Therapeutics CEO and Managing Director Mark Diamond said “The results of this most recent toxicology study and the human data to date are encouraging and re-ignite our hopes for this project. We are continuing to generate new data on ATL1102 which we believe will support positive interactions with the FDA in relation to our plans for a future Phase IIb trial in MS patients. We look forward to confirming our plans for the further clinical development of ATL1102 with the FDA in the coming months.”

Source: www.news-medical.net/ (02/04/14)